

Vivesto strengthens Cantrixil program with new preclinical results and patent application

Solna, Sweden, December 19, 2024 – Vivesto AB, an oncology-focused development company, today announced that positive results were obtained from preclinical studies with combination treatments within the company's Cantrixil program, supporting continued development in hematological cancer. Vivesto also announced that a new patent application covering the treatment of hematological cancer with Cantrixil was filed, with the aim to strengthen the IP position.

The drug candidate Cantrixil has been evaluated in further combination treatments with other anti-cancer drugs generating new in vitro data in hematological cancer cell lines. The results demonstrate clear positive effects of Cantrixil in combination with other anti-cancer drugs. The positive results confirm previous preclinical efficacy results and support continued development in hematological cancer. New results from hematological cancer models are expected to be presented throughout 2025.

"Hematological cancer is one of Vivesto's priority focus areas, and we are pleased to report successful results from yet another preclinical study supporting the further development of the Cantrixil program. We believe that Cantrixil can play a key role in the treatment of hematological cancer and look forward to reporting new data from additional ongoing studies early next year that will be of great importance as the program is developed towards clinical phase," said Erik Kinnman, CEO of Vivesto. "Vivesto also filed a new patent application for the treatment of hematological cancer with Cantrixil as a robust patent portfolio is fundamental for value creation in clinical development, and eventually, commercialization of the product."

Cantrixil has previously shown strong cytotoxic effects at low doses in cell lines derived from patients with hematological cancer. The recently generated data provides important input to the dosing selection and treatment regime in upcoming preclinical and clinical studies.

For More Information:

Erik Kinnman, Chief Executive Officer
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com

About Vivesto AB

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy.

Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.

Attachments

[Vivesto strengthens Cantrixil program with new preclinical results and patent application](#)